These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21269443)

  • 41. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment.
    Wagner S; Doering B; Helmreich I; Lieb K; Tadić A
    Acta Psychiatr Scand; 2012 Apr; 125(4):281-92. PubMed ID: 22007857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
    Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
    Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abnormal temporal difference reward-learning signals in major depression.
    Kumar P; Waiter G; Ahearn T; Milders M; Reid I; Steele JD
    Brain; 2008 Aug; 131(Pt 8):2084-93. PubMed ID: 18579575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder.
    Caudill MM; Hunter AM; Cook IA; Leuchter AF
    Clin EEG Neurosci; 2015 Oct; 46(4):277-84. PubMed ID: 25258429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma brain-derived neurotrophic factor (pBDNF) and executive dysfunctions in patients with major depressive disorder.
    Wagner S; Kayser S; Engelmann J; Schlicht KF; Dreimüller N; Tüscher O; Müller-Dahlhaus F; Braus DF; Tadić A; Neyazi A; Frieling H; Lieb K
    World J Biol Psychiatry; 2019 Sep; 20(7):519-530. PubMed ID: 29334322
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
    Reeves H; Batra S; May RS; Zhang R; Dahl DC; Li X
    J Clin Psychiatry; 2008 Aug; 69(8):1228-1236. PubMed ID: 18681749
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
    Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
    J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
    Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
    J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants.
    Lee HY; Kim YK
    Neuropsychobiology; 2008; 57(4):194-9. PubMed ID: 18679038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of major depressive disorder and prediction of treatment response using functional connectivity between the prefrontal cortices and subgenual anterior cingulate: A real-world study.
    Wang Q; Tian S; Tang H; Liu X; Yan R; Hua L; Shi J; Chen Y; Zhu R; Lu Q; Yao Z
    J Affect Disord; 2019 Jun; 252():365-372. PubMed ID: 30999093
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does early and late life depression differ in residual symptoms, functioning and quality of life among the first-episode major depressive patients.
    Xiao L; Zhou JJ; Feng Y; Zhu XQ; Wu WY; Hu YD; Niu YJ; Hu J; Wang XY; Gao CG; Zhang N; Fang YR; Liu TB; Jia FJ; Feng L; Wang G
    Asian J Psychiatr; 2020 Jan; 47():101843. PubMed ID: 31731143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of remission speed and improvement of cognitive functions of depressed patients.
    Gudayol-Ferré E; Guàrdia-Olmos J; Peró-Cebollero M
    Psychiatry Res; 2015 Mar; 226(1):103-12. PubMed ID: 25619432
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder.
    Miskowiak KW; Vinberg M; Harmer CJ; Ehrenreich H; Knudsen GM; Macoveanu J; Hansen AR; Paulson OB; Siebner HR; Kessing LV
    Trials; 2010 Oct; 11():97. PubMed ID: 20942940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis.
    Shi Y; Luan D; Song R; Zhang Z
    Eur Neuropsychopharmacol; 2020 Dec; 41():40-51. PubMed ID: 32980240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated levels of glutathionyl haemoglobin as an oxidative stress marker in patients with major depressive disorder.
    Mathew B; Srinivasan K; Johnson P; Thomas T; Mandal AK
    Indian J Med Res; 2019 Apr; 149(4):497-502. PubMed ID: 31411173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
    Clayton AH; Kennedy SH; Edwards JB; Gallipoli S; Reed CR
    J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder.
    He S; Liu X; Jiang K; Peng D; Hong W; Fang Y; Qian Y; Yu S; Li H
    J Psychiatr Res; 2016 Jul; 78():65-71. PubMed ID: 27078210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort.
    Fond G; Boyer L; Berna F; Godin O; Bulzacka E; Andrianarisoa M; Brunel L; Aouizerate B; Capdevielle D; Chereau I; Coulon N; D'Amato T; Dubertret C; Dubreucq J; Faget C; Leignier S; Lançon C; Mallet J; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Leboyer M; Schürhoff F; Llorca PM;
    Br J Psychiatry; 2018 Aug; 213(2):464-470. PubMed ID: 29871707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.